Literature DB >> 11244438

Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.

S Regn1, S Raffegerst, X Chen, D Schendel, H J Kolb, M Roskrow.   

Abstract

Human adenovirus (AdV) infection and EBV-lymphoproliferative disease (LPD) are serious complications following allogeneic stem cell transplantation. In the healthy individual these viruses cause minor, self-limiting diseases but in the immunocompromised patient they are responsible for significant morbidity and mortality. The limitations of anti-viral drugs and a better understanding of the cellular immune response to viral pathogens have prompted interest in developing adoptive immunotherapy for transplant patients. Ex vivo expanded cytotoxic T lymphocytes (CTLs) specific for EBV have been used effectively both as prophylaxis against EBV-LPD and as treatment of established EBV+ lymphoma. To generate CTLs specific for AdV, we infected immature dendritic cells with virus, in the presence of lipid, and subsequently used these cells to stimulate PBMNCs. Cytotoxicity assays showed that the resulting CTLs specifically lysed AdV-expressing targets and that this was mediated predominantly by CD4+ T cells. To generate CTLs specific for both AdV and EBV, we developed a CD40 ligand co-culture system to infect B-lymphoblastoid cell lines (LCLs) with high efficiency. PBMNCs from healthy AdV-seropositive donors were stimulated weekly with autologous AdV+-LCLs. Chromium release assays demonstrated that the resultant CTLs had specificity against both EBV and AdV and that this was mediated by both CD4+ and CD8+ T cells. Our findings have potential implications for post-transplant AdV and EBV immunotherapy in recipients of allogeneic stem cell transplants.

Entities:  

Mesh:

Year:  2001        PMID: 11244438     DOI: 10.1038/sj.bmt.1702752

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections.

Authors:  L Lenaerts; E Verbeken; E De Clercq; L Naesens
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 2.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

3.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

4.  Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses.

Authors:  F Zhu; G Ramadan; B Davies; D A Margolis; C A Keever-Taylor
Journal:  Clin Exp Immunol       Date:  2007-11-14       Impact factor: 4.330

5.  Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives.

Authors:  Ettore Biagi; Catherine Bollard; Raphael Rousseau; Malcolm Brenner
Journal:  J Biomed Biotechnol       Date:  2003

Review 6.  The challenge of respiratory virus infections in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh
Journal:  Br J Haematol       Date:  2008-09-10       Impact factor: 6.998

Review 7.  Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Ren Lin; Qifa Liu
Journal:  J Hematol Oncol       Date:  2013-12-17       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.